These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35091441)

  • 21. Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline
    de Bono J; Ramanathan RK; Mina L; Chugh R; Glaspy J; Rafii S; Kaye S; Sachdev J; Heymach J; Smith DC; Henshaw JW; Herriott A; Patterson M; Curtin NJ; Byers LA; Wainberg ZA
    Cancer Discov; 2017 Jun; 7(6):620-629. PubMed ID: 28242752
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD.
    Hodgson D; Lai Z; Dearden S; Barrett JC; Harrington EA; Timms K; Lanchbury J; Wu W; Allen A; Senkus E; Domchek SM; Robson M
    Ann Oncol; 2021 Dec; 32(12):1582-1589. PubMed ID: 34500047
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial.
    Ettl J; Quek RGW; Lee KH; Rugo HS; Hurvitz S; Gonçalves A; Fehrenbacher L; Yerushalmi R; Mina LA; Martin M; Roché H; Im YH; Markova D; Bhattacharyya H; Hannah AL; Eiermann W; Blum JL; Litton JK
    Ann Oncol; 2018 Sep; 29(9):1939-1947. PubMed ID: 30124753
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
    Litton JK; Rugo HS; Ettl J; Hurvitz SA; Gonçalves A; Lee KH; Fehrenbacher L; Yerushalmi R; Mina LA; Martin M; Roché H; Im YH; Quek RGW; Markova D; Tudor IC; Hannah AL; Eiermann W; Blum JL
    N Engl J Med; 2018 Aug; 379(8):753-763. PubMed ID: 30110579
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concordance Between Tumor and Germline BRCA Status in High-Grade Ovarian Carcinoma Patients in the Phase III PAOLA-1/ENGOT-ov25 Trial.
    Callens C; Vaur D; Soubeyran I; Rouleau E; Just PA; Guillerm E; Golmard L; Goardon N; Sevenet N; Cabaret O; Harter P; Gonzalez-Martin A; Fujiwara K; Cecere SC; Colombo N; Marth C; Vergote I; Maenpaa J; Pujade-Lauraine E; Ray-Coquard I
    J Natl Cancer Inst; 2021 Jul; 113(7):917-923. PubMed ID: 33372675
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of novel poly (ADP-ribose) inhibitors in the treatment of locally advanced and metastatic Her-2/neu negative breast cancer with inherited germline BRCA1/2 mutations. A review of the literature.
    Pop L; Suciu I; Ionescu O; Bacalbasa N; Ionescu P
    J Med Life; 2021; 14(1):17-20. PubMed ID: 33767780
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study.
    O'Shaughnessy J; Brezden-Masley C; Cazzaniga M; Dalvi T; Walker G; Bennett J; Ohsumi S
    Breast Cancer Res; 2020 Oct; 22(1):114. PubMed ID: 33109210
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic.
    Cerrato A; Morra F; Celetti A
    J Exp Clin Cancer Res; 2016 Nov; 35(1):179. PubMed ID: 27884198
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advances in PARP inhibitors for the treatment of breast cancer.
    Dizdar O; Arslan C; Altundag K
    Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of Somatically Acquired
    Vidula N; Dubash T; Lawrence MS; Simoneau A; Niemierko A; Blouch E; Nagy B; Roh W; Chirn B; Reeves BA; Malvarosa G; Lennerz J; Isakoff SJ; Juric D; Micalizzi D; Wander S; Spring L; Moy B; Shannon K; Younger J; Lanman R; Toner M; Iafrate AJ; Getz G; Zou L; Ellisen LW; Maheswaran S; Haber DA; Bardia A
    Clin Cancer Res; 2020 Sep; 26(18):4852-4862. PubMed ID: 32571788
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors.
    Dhawan MS; Bartelink IH; Aggarwal RR; Leng J; Zhang JZ; Pawlowska N; Terranova-Barberio M; Grabowsky JA; Gewitz A; Chien AJ; Moasser M; Kelley RK; Maktabi T; Thomas S; Munster PN
    Clin Cancer Res; 2017 Nov; 23(21):6400-6410. PubMed ID: 28790114
    [No Abstract]   [Full Text] [Related]  

  • 32. Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations.
    Jerez Y; Márquez-Rodas I; Aparicio I; Alva M; Martín M; López-Tarruella S
    Drugs; 2020 Feb; 80(2):131-146. PubMed ID: 31823331
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Talazoparib Exposure-Efficacy Analysis in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA Trial.
    Yu Y; Elmeliegy M; Litton JK; Tudor IC; Czibere A; Zheng J; Wang DD
    J Clin Pharmacol; 2020 Oct; 60(10):1324-1333. PubMed ID: 32468579
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
    Swisher EM; Lin KK; Oza AM; Scott CL; Giordano H; Sun J; Konecny GE; Coleman RL; Tinker AV; O'Malley DM; Kristeleit RS; Ma L; Bell-McGuinn KM; Brenton JD; Cragun JM; Oaknin A; Ray-Coquard I; Harrell MI; Mann E; Kaufmann SH; Floquet A; Leary A; Harding TC; Goble S; Maloney L; Isaacson J; Allen AR; Rolfe L; Yelensky R; Raponi M; McNeish IA
    Lancet Oncol; 2017 Jan; 18(1):75-87. PubMed ID: 27908594
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review.
    Mohyuddin GR; Aziz M; Britt A; Wade L; Sun W; Baranda J; Al-Rajabi R; Saeed A; Kasi A
    BMC Cancer; 2020 Jun; 20(1):507. PubMed ID: 32493233
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor Immune Microenvironment Changes by Multiplex Immunofluorescence Staining in a Pilot Study of Neoadjuvant Talazoparib for Early-Stage Breast Cancer Patients with a Hereditary BRCA Mutation.
    Kumar T; Hobbs E; Yang F; Chang JT; Contreras A; Cuentas ERP; Garber H; Lee S; Lu Y; Scoggins ME; Adrada BE; Whitman GJ; Arun BK; Mittendorf EA; Litton JK
    Clin Cancer Res; 2022 Sep; 28(17):3669-3676. PubMed ID: 35736816
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of talazoparib in Japanese patients with germline BRCA-mutated locally advanced or metastatic breast cancer: results of the phase 1 dose-expansion study.
    Kotani H; Masuda N; Yamashita T; Naito Y; Taira T; Inoue K; Takahashi M; Yonemori K; Toyoizumi S; Mori Y; Nagasawa T; Hori N; Iwata H
    Breast Cancer; 2022 Nov; 29(6):1088-1098. PubMed ID: 35907135
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A nano-liposome formulation of the PARP inhibitor Talazoparib enhances treatment efficacy and modulates immune cell populations in mammary tumors of BRCA-deficient mice.
    Zhang D; Baldwin P; Leal AS; Carapellucci S; Sridhar S; Liby KT
    Theranostics; 2019; 9(21):6224-6238. PubMed ID: 31534547
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination-deficient Pancreatic Cancer.
    Wang Y; Park JYP; Pacis A; Denroche RE; Jang GH; Zhang A; Cuggia A; Domecq C; Monlong J; Raitses-Gurevich M; Grant RC; Borgida A; Holter S; Stossel C; Bu S; Masoomian M; Lungu IM; Bartlett JMS; Wilson JM; Gao ZH; Riazalhosseini Y; Asselah J; Bouganim N; Cabrera T; Boucher LM; Valenti D; Biagi J; Greenwood CMT; Polak P; Foulkes WD; Golan T; O'Kane GM; Fischer SE; Knox JJ; Gallinger S; Zogopoulos G
    Clin Cancer Res; 2020 Oct; 26(20):5462-5476. PubMed ID: 32816949
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer.
    Taylor AM; Chan DLH; Tio M; Patil SM; Traina TA; Robson ME; Khasraw M
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011395. PubMed ID: 33886122
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.